Depression, Anxiety
Conditions
Keywords
Interpersonal Psychotherapy
Brief summary
This study will examine the feasibility and efficacy of a personalized psychotherapy treatment for people with depression and co-occurring anxiety.
Detailed description
Approximately one half of all depressed psychiatric patients also meet the criteria for an anxiety disorder. Compared to people with only depression, people with both depression and panic features experience poorer psychological and social functioning, a greater risk of suicide, less response to medication and therapy treatment, and a greater risk of recurring symptoms. Because people with depression and co-occurring anxiety features do not achieve full symptom remission with either medication or therapy alone, this study will use a treatment that combines the two. A commonly used type of depression medication called a selective serotonin reuptake inhibitor (SSRI) will be combined with a specialized therapy developed to address depression with co-occurring symptoms of panic, anxiety, and avoidance. This study will also test a computer-based method of assessing mood and anxiety symptom profiles and outcomes to determine whether participants find this method acceptable and clinicians find it useful. Participation in this study will last 20 weeks, with follow-up visits occurring 4 and 8 months after starting. Participants will be randomly assigned to receive either an individualized therapy for depression and anxiety, called interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS), or a standard therapy for depression, called brief supportive psychotherapy (BSP). All participants will complete up to 16 therapy sessions and receive a standard SSRI treatment with the medication citalopram hydrobromide. During the IPT-PS treatment, a study therapist will examine regular computer updates of depression and anxiety scores for participants and talk to them about identifying and addressing life stressors that trigger symptoms. During the BSP treatment, a study therapist will encourage participants to arrive at their own solutions by emphasizing the participants' strengths and examining what has worked in the past. Participants will complete assessments weekly during the 20 weeks of the study intervention and at 4- and 8-month follow-up visits. These assessments will include self-report questionnaires about symptoms, medication side effects, and treatment adherence; vital sign and weight measurements; and a clinical interview. Regular assessments of medication effectiveness and side effects will occur every 1 to 4 weeks. Starting at the second study visit, participants will also complete monthly computer-based questionnaires about depression and anxiety symptoms.
Interventions
BEHAVIORALInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)
16 weekly IPT-PS sessions, each lasting approximately 45 minutes
BEHAVIORALBrief Supportive Psychotherapy (BSP)
16 weekly BPS sessions, each lasting approximately 45 minutes
A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
Sponsors
National Institute of Mental Health (NIMH)
University of Pittsburgh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Currently in an episode of nonpsychotic major depression, as defined by the DSM-IV and documented by both the Structured Clinical Interview for Axis I, DSM-IV Disorders (SCID) and by a rating of greater than 15 on the 25-item Hamilton Rating Scale for Depression (HRSD) * Panic spectrum risk category of at least 7, as defined by the Panic-Agoraphobic Spectrum Self-Report (PAS-SR), last month version * Not currently receiving effective treatment * Participants with suicidal ideation are eligible as long as outpatient treatment is deemed safe.
Exclusion criteria
* History of manic or hypomanic episode(s) * History of schizophrenia or schizoaffective disorder * Mood disorder due to a general medical condition or induced by substance use * Presence of psychosis * Current pregnancy or plans to become pregnant * Current primary diagnosis of anorexia nervosa or bulimia nervosa (this does not include an eating disorder not otherwise specified \[NOS\]) * Current primary diagnosis of severe obsessive-compulsive disorder (OCD), as determined by clinician evaluation of symptom severity and temporal onset of symptoms * Drug or alcohol abuse or dependence within the past 3 months (participants with episodic abuse related to mood episodes will not be excluded) * Satisfies full DSM-IV criteria for antisocial personality disorder, as determined by SCID-II evaluation * Requires inpatient treatment because of suicidal risk or psychotic symptoms (current suicidal thinking or parasuicidal behavior is not exclusionary if, in clinician judgment, it can be managed on an outpatient basis) * Any of the following medical conditions: 1. An index episode that is secondary to the effect of medically prescribed drugs, i.e., reserpine, antihistamines, etc. 2. Presence of significant uncontrolled medical illness including cardiovascular disorder, kidney or liver disease, epilepsy, untreated hypertension, or unstabilized endocrine disease (stable medical conditions such as well-controlled diabetes or HIV positive status are not exclusionary provided the participant meets other inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Meeting Depression Remission Criteria | Measured at baseline and weekly for up to 20 weeks of acute treatment | Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, \< or = 7 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weeks to Depression Remission | Measured at baseline and weekly for up to 20 weeks of treatment | Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score \< or = 7 for three consecutive weeks). Analyses run with the full intent to treat sample (censoring patients who dropped out at time of termination) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Personalized Depression Care Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day | 24 |
| Standard Depression Care Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day | 26 |
| Total | 50 |
Baseline characteristics
| Characteristic | Personalized Depression Care | Standard Depression Care | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 24 Participants | 26 Participants | 50 Participants |
| Age, Continuous | 30.37 years STANDARD_DEVIATION 11.41 | 31.09 years STANDARD_DEVIATION 10.27 | 30.74 years STANDARD_DEVIATION 10.72 |
| Region of Enrollment United States | 24 participants | 26 participants | 50 participants |
| Sex: Female, Male Female | 19 Participants | 18 Participants | 37 Participants |
| Sex: Female, Male Male | 5 Participants | 8 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 24 | 1 / 26 |
| serious Total, serious adverse events | 0 / 24 | 0 / 26 |
Outcome results
Primary
Number of Participants Meeting Depression Remission Criteria
Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, \< or = 7
Time frame: Measured at baseline and weekly for up to 20 weeks of acute treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Personalized Depression Care | Number of Participants Meeting Depression Remission Criteria | 10 participants |
| Standard Depression Care | Number of Participants Meeting Depression Remission Criteria | 15 participants |
Secondary
Weeks to Depression Remission
Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score \< or = 7 for three consecutive weeks). Analyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)
Time frame: Measured at baseline and weekly for up to 20 weeks of treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Personalized Depression Care | Weeks to Depression Remission | 13.99 weeks | Standard Error 1.47 |
| Standard Depression Care | Weeks to Depression Remission | 11.59 weeks | Standard Error 1.31 |